Anthropic Kicks Off IPO Roadshow: Up to $64 Billion on Nasdaq Under the Ticker ANT

Anthropic has officially entered the home stretch toward the public market. The company has launched its roadshow: a series of meetings with institutional investors that determine the price at which, and the volume in which, the shares will be sold. For an industry where the largest labs have long lived on venture and corporate money, this is a notable shift.

What Exactly Is Being Sold

The release contains just three numbers worth remembering. A total of 825 million Class A common shares are being offered. Of these, Anthropic itself is selling 801,351,354 shares, and existing shareholders are selling 23,648,646. The indicative price is $70 to $78 per share. The listing is planned on the Nasdaq Global Select Market under the ticker ANT.

Let's do the back-of-the-envelope math. At this range, the whole deal is worth roughly $57.8–64.4 billion. Of that, the company's share is about $56.1–62.5 billion before underwriting commissions and expenses. The selling shareholders will receive roughly another $1.7–1.8 billion, and Anthropic will get none of that money. This is a standard arrangement: some early investors and employees lock in profits.

There is also a separate option for the underwriters: 30 days to purchase up to 123.75 million additional shares. That is exactly 15% of the base offering, the classic "greenshoe." If demand turns out to be strong, it could bring in roughly another $8.7–9.7 billion. The release names Goldman Sachs and Morgan Stanley as the banks from which a preliminary prospectus can be requested.

What the Release Does Not Say

It's important not to read too much into it. The press release gives no company valuation, and one cannot be calculated, because the total number of shares after the offering is not stated. There are also no financial figures: revenue, losses, compute costs. All of that will appear in the prospectus, which the release explicitly mentions. The SEC registration has been filed but has not yet become effective. Until then, the shares cannot be sold and orders to buy cannot be accepted. The price, the size, and even the offering itself may change.

The name also includes PBC, meaning public benefit corporation. This is a legal form in which, alongside shareholder interests, the company commits to a public purpose. How this status will coexist with the public market and quarterly reporting will become clear from the prospectus.

What This Changes in Practice

The release has no direct impact on the API, token prices, or models. But the indirect consequences for those building on Claude are quite real.

• Transparency. A public company is required to disclose risks, dependence on large customers and cloud providers, and its cost structure. For vendor assessment, this is a free source of data that did not exist before.
• Pressure on margins. Quarterly reporting often pushes companies to revisit pricing, limits, and terms for large customers. Build this into your product's unit economics.
• Supplier stability. Raising tens of billions of dollars reduces the risk that the lab will run out of money for training models and infrastructure. But the share price will fluctuate with market sentiment.

For founders there is also a market benchmark: a successful offering will set the bar for valuations across the whole segment, including startups built on top of foundation models.

Practical Takeaway

For now this is only an application to offer shares, not the outcome. When the prospectus becomes public, read the sections on risks and major customers, not the headlines about deal size. And don't build your architecture around a single vendor: even with the strongest balance sheet, a multi-model layer in your product remains cheap insurance.